Last reviewed · How we verify
Fimasartan, Rosuvastatin
Fimasartan is an angiotensin II receptor blocker that reduces blood pressure, while rosuvastatin is a statin that lowers cholesterol; together they address hypertension and dyslipidemia.
Fimasartan is an angiotensin II receptor blocker that reduces blood pressure, while rosuvastatin is a statin that lowers cholesterol; together they address hypertension and dyslipidemia. Used for Hypertension with dyslipidemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.
At a glance
| Generic name | Fimasartan, Rosuvastatin |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Angiotensin II receptor blocker + HMG-CoA reductase inhibitor (statin) |
| Target | AT1 receptor (fimasartan); HMG-CoA reductase (rosuvastatin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Fimasartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and reducing blood pressure. Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby lowering LDL cholesterol and triglycerides. This combination targets both hypertension and lipid abnormalities in cardiovascular disease management.
Approved indications
- Hypertension with dyslipidemia
- Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy
Common side effects
- Dizziness
- Headache
- Muscle pain or myalgia
- Elevated liver enzymes
- Hyperkalemia
Key clinical trials
- Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control
- Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia (PHASE4)
- Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia (PHASE3)
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects (PHASE1)
- Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation (PHASE4)
- A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin (PHASE1)
- A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia (PHASE3)
- A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fimasartan, Rosuvastatin CI brief — competitive landscape report
- Fimasartan, Rosuvastatin updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI